OncoMatch/Clinical Trials/NCT07164313
A Study of ZW251 in Participants With Advanced Solid Tumors
Is NCT07164313 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ZW251 for hepatocellular carcinoma.
Treatment: ZW251 — The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate organ function
Kidney function
Acute or chronic uncontrolled renal disease excluded
Liver function
Liver function status of Child-Pugh Class A
Liver function status of Child-Pugh Class A; Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCSF Comprehensive Cancer Center · San Francisco, California
- Norton Cancer Institute · Louisville, Kentucky
- START Midwest · Grand Rapids, Michigan
- Hackensack University Medical Center · Hackensack, New Jersey
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify